世界の移植片対宿主病（GVHD）治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Graft Versus Host Disease (GVHD) Treatment Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z2621
• 出版社/出版日：QYResearch / 2021年4月
※2025年版があります。お問い合わせください。
• レポート形態：英文、PDF、128ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査資料では、移植片対宿主病（GVHD）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（モノクローナル抗体、MTOR阻害剤、チロシンキナーゼ阻害剤、サリドマイド、エタネルセプト）、用途別市場規模（急性移植片対宿主病（aGvHD）、慢性移植片対宿主病（cGvHD））、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。
・市場概要
・移植片対宿主病（GVHD）治療の市場動向
・企業の競争状況、市場シェア
・移植片対宿主病（GVHD）治療の種類別市場規模（モノクローナル抗体、MTOR阻害剤、チロシンキナーゼ阻害剤、サリドマイド、エタネルセプト）
・移植片対宿主病（GVHD）治療の用途別市場規模（急性移植片対宿主病（aGvHD）、慢性移植片対宿主病（cGvHD））
・移植片対宿主病（GVHD）治療の北米市場規模2016-2027（アメリカ、カナダ）
・移植片対宿主病（GVHD）治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等）
・移植片対宿主病（GVHD）治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・移植片対宿主病（GVHD）治療の中南米市場規模2016-2027（メキシコ、ブラジル）
・移植片対宿主病（GVHD）治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Bristol-Myers Squibb、Abbott、AbbVie、Allergan、Anterogen、Astellas Pharma、Athersys、Caladrius、Eli Lilly、GlaxoSmithKline、Glenmark、Kadmon Holdings、Osiris Therapeutics、Sanofi、Takeda）
・結論

Graft versus Host disease occurs after a stem cell or bone marrow transplant. High dose treatment destroy cancer cells along with that it simultaneously destroys healthy cells. Stem cell and bone marrow transplant treatments are used in reconstructing damaged cells, surrounding cancer tumors. Normally after high dose treatment, patient receives bone marrow from a donor through drip which resumes production of blood cells. Graft versus Host Disease occurs when certain types of white blood cells. This is caused due to the transplanted cells (graft) see recipient’s body (host) as exotic, thus transplanted cells attack the host body.
The growing number of organ transplantation cases as one of the major factors that will have a positive impact on the growth of the market. The rise in chronic diseases across the globe has led to the growth in the need for organ transplantation. It has been observed that in 2015, the US witnessed more than 30,000 organ transplants cases, which has increased about 5% when compared to the previous year. Similarly, countries such as Australia also witnesses increasing cases of organ transplantation. This rising number of organ transplants will subsequently augment the growth prospects of the GVHD treatment market.

Market Analysis and Insights: Global Graft Versus Host Disease (GVHD) Treatment Market
The global Graft Versus Host Disease (GVHD) Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Graft Versus Host Disease (GVHD) Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Graft Versus Host Disease (GVHD) Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Graft Versus Host Disease (GVHD) Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Graft Versus Host Disease (GVHD) Treatment market.

Global Graft Versus Host Disease (GVHD) Treatment Scope and Market Size
Graft Versus Host Disease (GVHD) Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Graft Versus Host Disease (GVHD) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Monoclonal Antibodies
MTOR Inhibitors
Tyrosine Kinase Inhibitors
Thalidomide
Etanercept

Segment by Application
Acute Graft Versus Host Disease (aGvHD)
Chronic Graft Versus Host Disease (cGvHD)

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Bristol-Myers Squibb
Abbott
AbbVie
Allergan
Anterogen
Astellas Pharma
Athersys
Caladrius
Eli Lilly
Allergan
Anterogen
Kadmon Holdings
Osiris Therapeutics

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Graft Versus Host Disease (GVHD) Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Monoclonal Antibodies
1.2.3 MTOR Inhibitors
1.2.4 Tyrosine Kinase Inhibitors
1.2.5 Thalidomide
1.2.6 Etanercept
1.3 Market by Application
1.3.1 Global Graft Versus Host Disease (GVHD) Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Acute Graft Versus Host Disease (aGvHD)
1.3.3 Chronic Graft Versus Host Disease (cGvHD)
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Graft Versus Host Disease (GVHD) Treatment Market Perspective (2016-2027)
2.2 Graft Versus Host Disease (GVHD) Treatment Growth Trends by Regions
2.2.1 Graft Versus Host Disease (GVHD) Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Graft Versus Host Disease (GVHD) Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Graft Versus Host Disease (GVHD) Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Graft Versus Host Disease (GVHD) Treatment Industry Dynamic
2.3.1 Graft Versus Host Disease (GVHD) Treatment Market Trends
2.3.2 Graft Versus Host Disease (GVHD) Treatment Market Drivers
2.3.3 Graft Versus Host Disease (GVHD) Treatment Market Challenges
2.3.4 Graft Versus Host Disease (GVHD) Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Graft Versus Host Disease (GVHD) Treatment Players by Revenue
3.1.1 Global Top Graft Versus Host Disease (GVHD) Treatment Players by Revenue (2016-2021)
3.1.2 Global Graft Versus Host Disease (GVHD) Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Graft Versus Host Disease (GVHD) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Graft Versus Host Disease (GVHD) Treatment Revenue
3.4 Global Graft Versus Host Disease (GVHD) Treatment Market Concentration Ratio
3.4.1 Global Graft Versus Host Disease (GVHD) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Graft Versus Host Disease (GVHD) Treatment Revenue in 2020
3.5 Graft Versus Host Disease (GVHD) Treatment Key Players Head office and Area Served
3.6 Key Players Graft Versus Host Disease (GVHD) Treatment Product Solution and Service
3.7 Date of Enter into Graft Versus Host Disease (GVHD) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Graft Versus Host Disease (GVHD) Treatment Breakdown Data by Type
4.1 Global Graft Versus Host Disease (GVHD) Treatment Historic Market Size by Type (2016-2021)
4.2 Global Graft Versus Host Disease (GVHD) Treatment Forecasted Market Size by Type (2022-2027)

5 Graft Versus Host Disease (GVHD) Treatment Breakdown Data by Application
5.1 Global Graft Versus Host Disease (GVHD) Treatment Historic Market Size by Application (2016-2021)
5.2 Global Graft Versus Host Disease (GVHD) Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Graft Versus Host Disease (GVHD) Treatment Market Size (2016-2027)
6.2 North America Graft Versus Host Disease (GVHD) Treatment Market Size by Type
6.2.1 North America Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2016-2021)
6.2.2 North America Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2022-2027)
6.2.3 North America Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2016-2027)
6.3 North America Graft Versus Host Disease (GVHD) Treatment Market Size by Application
6.3.1 North America Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2016-2021)
6.3.2 North America Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2022-2027)
6.3.3 North America Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2016-2027)
6.4 North America Graft Versus Host Disease (GVHD) Treatment Market Size by Country
6.4.1 North America Graft Versus Host Disease (GVHD) Treatment Market Size by Country (2016-2021)
6.4.2 North America Graft Versus Host Disease (GVHD) Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Graft Versus Host Disease (GVHD) Treatment Market Size (2016-2027)
7.2 Europe Graft Versus Host Disease (GVHD) Treatment Market Size by Type
7.2.1 Europe Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2016-2021)
7.2.2 Europe Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2022-2027)
7.2.3 Europe Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2016-2027)
7.3 Europe Graft Versus Host Disease (GVHD) Treatment Market Size by Application
7.3.1 Europe Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2016-2021)
7.3.2 Europe Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2022-2027)
7.3.3 Europe Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2016-2027)
7.4 Europe Graft Versus Host Disease (GVHD) Treatment Market Size by Country
7.4.1 Europe Graft Versus Host Disease (GVHD) Treatment Market Size by Country (2016-2021)
7.4.2 Europe Graft Versus Host Disease (GVHD) Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Market Size (2016-2027)
8.2 Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Market Size by Type
8.2.1 Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Market Size by Application
8.3.1 Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Market Size by Region
8.4.1 Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Graft Versus Host Disease (GVHD) Treatment Market Size (2016-2027)
9.2 Latin America Graft Versus Host Disease (GVHD) Treatment Market Size by Type
9.2.1 Latin America Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2016-2027)
9.3 Latin America Graft Versus Host Disease (GVHD) Treatment Market Size by Application
9.3.1 Latin America Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2016-2027)
9.4 Latin America Graft Versus Host Disease (GVHD) Treatment Market Size by Country
9.4.1 Latin America Graft Versus Host Disease (GVHD) Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Graft Versus Host Disease (GVHD) Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Graft Versus Host Disease (GVHD) Treatment Market Size (2016-2027)
10.2 Middle East & Africa Graft Versus Host Disease (GVHD) Treatment Market Size by Type
10.2.1 Middle East & Africa Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Graft Versus Host Disease (GVHD) Treatment Market Size by Application
10.3.1 Middle East & Africa Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Graft Versus Host Disease (GVHD) Treatment Market Size by Country
10.4.1 Middle East & Africa Graft Versus Host Disease (GVHD) Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Graft Versus Host Disease (GVHD) Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Details
11.1.2 Bristol-Myers Squibb Business Overview
11.1.3 Bristol-Myers Squibb Graft Versus Host Disease (GVHD) Treatment Introduction
11.1.4 Bristol-Myers Squibb Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021)
11.1.5 Bristol-Myers Squibb Recent Development
11.2 Abbott
11.2.1 Abbott Company Details
11.2.2 Abbott Business Overview
11.2.3 Abbott Graft Versus Host Disease (GVHD) Treatment Introduction
11.2.4 Abbott Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021)
11.2.5 Abbott Recent Development
11.3 AbbVie
11.3.1 AbbVie Company Details
11.3.2 AbbVie Business Overview
11.3.3 AbbVie Graft Versus Host Disease (GVHD) Treatment Introduction
11.3.4 AbbVie Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021)
11.3.5 AbbVie Recent Development
11.4 Allergan
11.4.1 Allergan Company Details
11.4.2 Allergan Business Overview
11.4.3 Allergan Graft Versus Host Disease (GVHD) Treatment Introduction
11.4.4 Allergan Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021)
11.4.5 Allergan Recent Development
11.5 Anterogen
11.5.1 Anterogen Company Details
11.5.2 Anterogen Business Overview
11.5.3 Anterogen Graft Versus Host Disease (GVHD) Treatment Introduction
11.5.4 Anterogen Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021)
11.5.5 Anterogen Recent Development
11.6 Astellas Pharma
11.6.1 Astellas Pharma Company Details
11.6.2 Astellas Pharma Business Overview
11.6.3 Astellas Pharma Graft Versus Host Disease (GVHD) Treatment Introduction
11.6.4 Astellas Pharma Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021)
11.6.5 Astellas Pharma Recent Development
11.7 Athersys
11.7.1 Athersys Company Details
11.7.2 Athersys Business Overview
11.7.3 Athersys Graft Versus Host Disease (GVHD) Treatment Introduction
11.7.4 Athersys Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021)
11.7.5 Athersys Recent Development
11.8 Caladrius
11.8.1 Caladrius Company Details
11.8.2 Caladrius Business Overview
11.8.3 Caladrius Graft Versus Host Disease (GVHD) Treatment Introduction
11.8.4 Caladrius Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021)
11.8.5 Caladrius Recent Development
11.9 Eli Lilly
11.9.1 Eli Lilly Company Details
11.9.2 Eli Lilly Business Overview
11.9.3 Eli Lilly Graft Versus Host Disease (GVHD) Treatment Introduction
11.9.4 Eli Lilly Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021)
11.9.5 Eli Lilly Recent Development
11.10 GlaxoSmithKline
11.10.1 GlaxoSmithKline Company Details
11.10.2 GlaxoSmithKline Business Overview
11.10.3 GlaxoSmithKline Graft Versus Host Disease (GVHD) Treatment Introduction
11.10.4 GlaxoSmithKline Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021)
11.10.5 GlaxoSmithKline Recent Development
11.11 Glenmark
11.11.1 Glenmark Company Details
11.11.2 Glenmark Business Overview
11.11.3 Glenmark Graft Versus Host Disease (GVHD) Treatment Introduction
11.11.4 Glenmark Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021)
11.11.5 Glenmark Recent Development
11.12 Kadmon Holdings
11.12.1 Kadmon Holdings Company Details
11.12.2 Kadmon Holdings Business Overview
11.12.3 Kadmon Holdings Graft Versus Host Disease (GVHD) Treatment Introduction
11.12.4 Kadmon Holdings Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021)
11.12.5 Kadmon Holdings Recent Development
11.13 Osiris Therapeutics
11.13.1 Osiris Therapeutics Company Details
11.13.2 Osiris Therapeutics Business Overview
11.13.3 Osiris Therapeutics Graft Versus Host Disease (GVHD) Treatment Introduction
11.13.4 Osiris Therapeutics Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021)
11.13.5 Osiris Therapeutics Recent Development
11.14 Sanofi
11.14.1 Sanofi Company Details
11.14.2 Sanofi Business Overview
11.14.3 Sanofi Graft Versus Host Disease (GVHD) Treatment Introduction
11.14.4 Sanofi Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021)
11.14.5 Sanofi Recent Development
11.15 Takeda
11.15.1 Takeda Company Details
11.15.2 Takeda Business Overview
11.15.3 Takeda Graft Versus Host Disease (GVHD) Treatment Introduction
11.15.4 Takeda Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021)
11.15.5 Takeda Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Graft Versus Host Disease (GVHD) Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Monoclonal Antibodies
Table 3. Key Players of MTOR Inhibitors
Table 4. Key Players of Tyrosine Kinase Inhibitors
Table 5. Key Players of Thalidomide
Table 6. Key Players of Etanercept
Table 7. Global Graft Versus Host Disease (GVHD) Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Graft Versus Host Disease (GVHD) Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Graft Versus Host Disease (GVHD) Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Graft Versus Host Disease (GVHD) Treatment Market Share by Regions (2016-2021)
Table 11. Global Graft Versus Host Disease (GVHD) Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Graft Versus Host Disease (GVHD) Treatment Market Share by Regions (2022-2027)
Table 13. Graft Versus Host Disease (GVHD) Treatment Market Trends
Table 14. Graft Versus Host Disease (GVHD) Treatment Market Drivers
Table 15. Graft Versus Host Disease (GVHD) Treatment Market Challenges
Table 16. Graft Versus Host Disease (GVHD) Treatment Market Restraints
Table 17. Global Graft Versus Host Disease (GVHD) Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Graft Versus Host Disease (GVHD) Treatment Market Share by Players (2016-2021)
Table 19. Global Top Graft Versus Host Disease (GVHD) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Graft Versus Host Disease (GVHD) Treatment as of 2020)
Table 20. Ranking of Global Top Graft Versus Host Disease (GVHD) Treatment Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Graft Versus Host Disease (GVHD) Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Graft Versus Host Disease (GVHD) Treatment Product Solution and Service
Table 24. Date of Enter into Graft Versus Host Disease (GVHD) Treatment Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Graft Versus Host Disease (GVHD) Treatment Revenue Market Share by Type (2016-2021)
Table 28. Global Graft Versus Host Disease (GVHD) Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Graft Versus Host Disease (GVHD) Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Graft Versus Host Disease (GVHD) Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Graft Versus Host Disease (GVHD) Treatment Revenue Market Share by Application (2016-2021)
Table 32. Global Graft Versus Host Disease (GVHD) Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Graft Versus Host Disease (GVHD) Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Graft Versus Host Disease (GVHD) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Graft Versus Host Disease (GVHD) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Graft Versus Host Disease (GVHD) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Graft Versus Host Disease (GVHD) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Graft Versus Host Disease (GVHD) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Graft Versus Host Disease (GVHD) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Graft Versus Host Disease (GVHD) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Graft Versus Host Disease (GVHD) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 64. Bristol-Myers Squibb Company Details
Table 65. Bristol-Myers Squibb Business Overview
Table 66. Bristol-Myers Squibb Graft Versus Host Disease (GVHD) Treatment Product
Table 67. Bristol-Myers Squibb Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021) & (US$ Million)
Table 68. Bristol-Myers Squibb Recent Development
Table 69. Abbott Company Details
Table 70. Abbott Business Overview
Table 71. Abbott Graft Versus Host Disease (GVHD) Treatment Product
Table 72. Abbott Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021) & (US$ Million)
Table 73. Abbott Recent Development
Table 74. AbbVie Company Details
Table 75. AbbVie Business Overview
Table 76. AbbVie Graft Versus Host Disease (GVHD) Treatment Product
Table 77. AbbVie Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021) & (US$ Million)
Table 78. AbbVie Recent Development
Table 79. Allergan Company Details
Table 80. Allergan Business Overview
Table 81. Allergan Graft Versus Host Disease (GVHD) Treatment Product
Table 82. Allergan Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021) & (US$ Million)
Table 83. Allergan Recent Development
Table 84. Anterogen Company Details
Table 85. Anterogen Business Overview
Table 86. Anterogen Graft Versus Host Disease (GVHD) Treatment Product
Table 87. Anterogen Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021) & (US$ Million)
Table 88. Anterogen Recent Development
Table 89. Astellas Pharma Company Details
Table 90. Astellas Pharma Business Overview
Table 91. Astellas Pharma Graft Versus Host Disease (GVHD) Treatment Product
Table 92. Astellas Pharma Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021) & (US$ Million)
Table 93. Astellas Pharma Recent Development
Table 94. Athersys Company Details
Table 95. Athersys Business Overview
Table 96. Athersys Graft Versus Host Disease (GVHD) Treatment Product
Table 97. Athersys Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021) & (US$ Million)
Table 98. Athersys Recent Development
Table 99. Caladrius Company Details
Table 100. Caladrius Business Overview
Table 101. Caladrius Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021) & (US$ Million)
Table 102. Caladrius Recent Development
Table 103. Eli Lilly Company Details
Table 104. Eli Lilly Business Overview
Table 105. Eli Lilly Graft Versus Host Disease (GVHD) Treatment Product
Table 106. Eli Lilly Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021) & (US$ Million)
Table 107. Eli Lilly Recent Development
Table 108. GlaxoSmithKline Company Details
Table 109. GlaxoSmithKline Business Overview
Table 110. GlaxoSmithKline Graft Versus Host Disease (GVHD) Treatment Product
Table 111. GlaxoSmithKline Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021) & (US$ Million)
Table 112. GlaxoSmithKline Recent Development
Table 113. Glenmark Company Details
Table 114. Glenmark Business Overview
Table 115. Glenmark Graft Versus Host Disease (GVHD) Treatment Product
Table 116. Glenmark Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021) & (US$ Million)
Table 117. Glenmark Recent Development
Table 118. Kadmon Holdings Company Details
Table 119. Kadmon Holdings Business Overview
Table 120. Kadmon Holdings Graft Versus Host Disease (GVHD) Treatment Product
Table 121. Kadmon Holdings Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021) & (US$ Million)
Table 122. Kadmon Holdings Recent Development
Table 123. Osiris Therapeutics Company Details
Table 124. Osiris Therapeutics Business Overview
Table 125. Osiris Therapeutics Graft Versus Host Disease (GVHD) Treatment Product
Table 126. Osiris Therapeutics Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021) & (US$ Million)
Table 127. Osiris Therapeutics Recent Development
Table 128. Sanofi Company Details
Table 129. Sanofi Business Overview
Table 130. Sanofi Graft Versus Host Disease (GVHD) Treatment Product
Table 131. Sanofi Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021) & (US$ Million)
Table 132. Sanofi Recent Development
Table 133. Takeda Company Details
Table 134. Takeda Business Overview
Table 135. Takeda Graft Versus Host Disease (GVHD) Treatment Product
Table 136. Takeda Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021) & (US$ Million)
Table 137. Takeda Recent Development
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Graft Versus Host Disease (GVHD) Treatment Market Share by Type: 2020 VS 2027
Figure 2. Monoclonal Antibodies Features
Figure 3. MTOR Inhibitors Features
Figure 4. Tyrosine Kinase Inhibitors Features
Figure 5. Thalidomide Features
Figure 6. Etanercept Features
Figure 7. Global Graft Versus Host Disease (GVHD) Treatment Market Share by Application: 2020 VS 2027
Figure 8. Acute Graft Versus Host Disease (aGvHD) Case Studies
Figure 9. Chronic Graft Versus Host Disease (cGvHD) Case Studies
Figure 10. Graft Versus Host Disease (GVHD) Treatment Report Years Considered
Figure 11. Global Graft Versus Host Disease (GVHD) Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Graft Versus Host Disease (GVHD) Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Graft Versus Host Disease (GVHD) Treatment Market Share by Regions: 2020 VS 2027
Figure 14. Global Graft Versus Host Disease (GVHD) Treatment Market Share by Regions (2022-2027)
Figure 15. Global Graft Versus Host Disease (GVHD) Treatment Market Share by Players in 2020
Figure 16. Global Top Graft Versus Host Disease (GVHD) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Graft Versus Host Disease (GVHD) Treatment as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Graft Versus Host Disease (GVHD) Treatment Revenue in 2020
Figure 18. Global Graft Versus Host Disease (GVHD) Treatment Revenue Market Share by Type (2016-2021)
Figure 19. Global Graft Versus Host Disease (GVHD) Treatment Revenue Market Share by Type (2022-2027)
Figure 20. North America Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Graft Versus Host Disease (GVHD) Treatment Market Share by Type (2016-2027)
Figure 22. North America Graft Versus Host Disease (GVHD) Treatment Market Share by Application (2016-2027)
Figure 23. North America Graft Versus Host Disease (GVHD) Treatment Market Share by Country (2016-2027)
Figure 24. United States Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Graft Versus Host Disease (GVHD) Treatment Market Share by Type (2016-2027)
Figure 28. Europe Graft Versus Host Disease (GVHD) Treatment Market Share by Application (2016-2027)
Figure 29. Europe Graft Versus Host Disease (GVHD) Treatment Market Share by Country (2016-2027)
Figure 30. Germany Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Market Share by Region (2016-2027)
Figure 40. China Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Graft Versus Host Disease (GVHD) Treatment Market Share by Type (2016-2027)
Figure 48. Latin America Graft Versus Host Disease (GVHD) Treatment Market Share by Application (2016-2027)
Figure 49. Latin America Graft Versus Host Disease (GVHD) Treatment Market Share by Country (2016-2027)
Figure 50. Mexico Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Graft Versus Host Disease (GVHD) Treatment Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Graft Versus Host Disease (GVHD) Treatment Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Graft Versus Host Disease (GVHD) Treatment Market Share by Country (2016-2027)
Figure 56. Turkey Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Bristol-Myers Squibb Revenue Growth Rate in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021)
Figure 60. Abbott Revenue Growth Rate in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021)
Figure 61. AbbVie Revenue Growth Rate in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021)
Figure 62. Allergan Revenue Growth Rate in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021)
Figure 63. Anterogen Revenue Growth Rate in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021)
Figure 64. Astellas Pharma Revenue Growth Rate in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021)
Figure 65. Athersys Revenue Growth Rate in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021)
Figure 66. Caladrius Revenue Growth Rate in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021)
Figure 67. Eli Lilly Revenue Growth Rate in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021)
Figure 68. GlaxoSmithKline Revenue Growth Rate in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021)
Figure 69. Glenmark Revenue Growth Rate in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021)
Figure 70. Kadmon Holdings Revenue Growth Rate in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021)
Figure 71. Osiris Therapeutics Revenue Growth Rate in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021)
Figure 72. Sanofi Revenue Growth Rate in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021)
Figure 73. Takeda Revenue Growth Rate in Graft Versus Host Disease (GVHD) Treatment Business (2016-2021)
Figure 74. Bottom-up and Top-down Approaches for This Report
Figure 75. Data Triangulation
Figure 76. Key Executives Interviewed

Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z0301 2021年4月 90Pages
QYResearch社発行の本調査資料では、筋萎縮性側索硬化症（ルーゲーリック病）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（化学療法、幹細胞治療）、用途別市場規模（病院、診断センター、クリニック、小売薬局）、主要地域別市場規模（北米、...

世界の炎症性腸疾患（IBD）治療市場規模・現状・予測（2021年-2027年）

Global Inflammatory Bowel Disease (IBD) Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z3158 2021年4月 94Pages
QYResearch社発行の本調査資料では、炎症性腸疾患（IBD）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（TNF阻害剤、アミノサリサイクレート、免疫調節剤、コルチコステロイド）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、...

世界の筋萎縮性側索硬化症（ルーゲーリック病）治療市場規模・現状・予測（2021年-2027年）

世界のクローン病診断・治療市場規模・現状・予測（2021年-2027年）

Global Crohn’s Disease Diagnostic and Therapeutic Market Size, Status and Forecast 2021-2027
QYR2104Z1651 2021年4月 94Pages
QYResearch社発行の本調査資料では、クローン病診断・治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（診断、治療）、用途別市場規模（病院、医学研究機関、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国...

世界のクローン病診断・治療市場規模・現状・予測（2021年-2027年）

世界の急性リンパ性白血病（ALL）治療市場規模・現状・予測（2021年-2027年）

Global Acute Lymphoid Leukemia Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z0071 2021年4月 94Pages
QYResearch社発行の本調査資料では、急性リンパ性白血病（ALL）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（化学療法、標的療法、放射線療法、骨髄移植、免疫療法、その他）、用途別市場規模（成人、子供）、主要地域別市場規模（北米、ア...

世界の胃食道逆流症（GERD）治療市場規模・現状・予測（2021年-2027年）

Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size, Status and Forecast 2021-2027
QYR2104Z2493 2021年4月 96Pages
QYResearch社発行の本調査資料では、胃食道逆流症（GERD）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（制酸剤、運動促進薬、H2受容体遮断薬、プロトンポンプ阻害薬（PPI））、用途別市場規模（胸焼け、胃酸逆流症）、主要地域別市場...

世界の胃食道逆流症（GERD）治療市場規模・現状・予測（2021年-2027年）

Global Gastroesophageal Reflux Disease Therapeutics Market Size, Status and Forecast 2021-2027
QYR2104Z2494 2021年4月 93Pages
QYResearch社発行の本調査資料では、胃食道逆流症（GERD）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（制酸剤、H2受容体遮断薬、プロトンポンプ阻害薬（PPI）、運動促進薬、その他）、用途別市場規模（病院薬局、ドラッグストア、雑...

世界の腸疾患検査・治療市場規模・現状・予測（2021年-2027年）

Global Enteric Disease Testing and Therapeutic Market Size, Status and Forecast 2021-2027
QYR2104Z2195 2021年4月 95Pages
QYResearch社発行の本調査資料では、腸疾患検査・治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（細菌性疾患、ウイルス性疾患、寄生虫性疾患）、用途別市場規模（病院、研究）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、...

世界のクローン病診断・治療市場規模・現状・予測（2021年-2027年）

Global Crohn's Disease Diagnostic and Therapeutic Market Size, Status and Forecast 2021-2027
QYR2104Z1652 2021年4月 94Pages
QYResearch社発行の本調査資料では、クローン病診断・治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（血液検査、糞便検査、結腸内視鏡検査、フレキシブルS状結腸鏡検査、コンピューター断層撮影、磁気共鳴画像法、カプセル内視鏡検査）、用途別...

世界のブルトン型チロシンキナーゼ（BTK）阻害剤市場規模・現状・予測（2021年-2027年） Bruton's tyrosine kinase (Btk), a member of the non-receptor tyrosine kinase Tec family, is a key signaling enzyme expressed in all hematopoietic cell types except T lymphocytes and natural killer cells.Btk plays a crucial role in stimulating B cell signaling pathways that connect the cell surface B…
世界の宿主細胞汚染物質試験市場規模・現状・予測（2021年-2027年） Host cell proteins essentially refers to the heterogeneous group of proteins that are derived from host cells such as yeast, E-coli, and mammal, among others. They differ largely form each other in terms of properties, isoelectric point, and molecular mass. Identification and quantification of host …
世界の凍結植皮市場規模・現状・予測（2021年-2027年） Cultured epidermal cells had been utilized for the treatment of burn skin. However new application and culture techniques have led to growing consumer attraction towards frozen skin graft. Market Analysis and Insights: Global Frozen Skin Graft Market The global Frozen Skin Graft market size is proj…
世界の生分解性骨移植ポリマー市場規模・現状・予測（2021年-2027年） Biodegradable Bone Graft Polymers is profoundly carving an evolution tale from conventional allogeneic and autologous bone grafting techniques to synthetic bone grafts, primarily on account of the biodegradability and biocompatibility properties of the latter. Synthetic bone graft polymers are capab…
世界の生分解性骨移植ポリマー市場規模・現状・予測（2021年-2027年） Biodegradable Bone Graft Polymers is profoundly carving an evolution tale from conventional allogeneic and autologous bone grafting techniques to synthetic bone grafts, primarily on account of the biodegradability and biocompatibility properties of the latter. Synthetic bone graft polymers are capab…